Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GUIDE.MRD

Financiado

GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most canc... ver más

30/04/2028

UKE

34M€

Presupuesto del proyecto: 34M€

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 28 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-17

HORIZON-JU-IHI-2022-01-03: Personalised oncology: innovative p... ExpectedOutcome:R&I actions to be supported under this topic shall contribute to all the followi...

I+D

Cerrada hace 2 años

0% 51% 100%

28 Participantes

UKE

2.35M€ | Lider

FUNDACION SECTOR PUBLICO EST...

1.27M€ | Participante

1.14M€ | Participante

TAT

276.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FG_WIT AUTOMATED PROTOTYPE OF CANCER DETECTION FROM CTDNA 75K€ Cerrado

PID2020-120306RB-I00 INTEGRAL STAGING, PROGNOSTIC AND DIAGNOSTIC OF CANCER IN LIQ... 184K€ Cerrado

CANCER-ID Cancer treatment and monitoring through identification of ci... 21M€ Cerrado

CTQ2017-85658-R TG-DIAG: NUEVAS ESTRATEGIAS DE DIAGNOSTICO BASADAS EN FLUORE... 116K€ Cerrado

BiopSense Proof of concept and pre commercialisation of personalised l... 150K€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2023-05-17
Fecha Fin: 2028-04-30

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 34M€

Descripción del proyecto Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies. For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated. Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual disease (MRD) in individual cancer patients, especially for selecting patients for multi-modal therapies post-operatively. However, despite many circulating tumor DNA (ctDNA) diagnostics being developed there is a lack of standardization, harmonization, and robust data to demonstrate clinical validity. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, and experts in multi-stakeholder engagements. Together, we will tackle the critical questions by developing reference standards for ctDNA diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a non-invasive diagnostic test. With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multi-modal therapy selection to improve patient outcomes.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores